Please assess the completion status of the following clinical trial:

Trial Title: Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 12 years or older~* Blood culture positive for S. aureus~* At least two signs or symptoms attributable to S. aureus BSI/IE~* Known or suspected complicated S. aureus BSI and/or right-sided IE based on Modified Duke Criteria~* Not pregnant or breastfeeding and not of reproductive potential or agrees to remain abstinent or use contraception if of reproductive potential~Exclusion Criteria:~* Previously received exebacase~* Known or suspected left-sided IE~* Treatment with effective systemic anti-staphylococcal antibiotic for more than 72 hours within 7 days before randomization~* Presence of prosthetic valve or cardiac valve support ring, or presence of known or suspected infected hardware (orthopedic), prosthetic joint, or cardiac device~* Known polymicrobial BSI, or known ongoing systemic infection caused by other bacterial and/or fungal pathogen(s), and/or known to have coronavirus disease 2019 (COVID-19)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exebacase (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).